Index Entries

February 4, 2020, updated March 7, 2023
CDC (Centers for Disease Control & Prevention)

Interpretation of Results and Reporting

2019-nCoV Markers (N1 and N2)…

When all controls exhibit the expected performance, a specimen is considered positive for 2019-nCoV if all 2019-nCoV marker (N1, N2) cycle threshold growth curves cross the threshold line within 40.00 cycles (< 40.00 Ct). The RNase P may or may not be positive as described above, but the 2019-nCoV result is still valid...

Analytical Performance: ...

The analytical sensitivity of the rRT-PCR assays contained in the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel were determined in Limit of Detection studies. Since no quantified virus isolates of the 2019-nCoV were available for CDC use at the time the test was developed and this study conducted, assays designed for detection of the 2019-nCoV RNA were tested with characterized stocks of in vitro transcribed full length RNA (N gene; GenBank accession: MN908947.2) of known titer (RNA copies/μL) spiked into a diluent consisting of a suspension of human A549 cells and viral transport medium (VTM) to mimic clinical specimen.

CDC-006-00019, Revision: 08, Effective: 03/07/2023

document
COVID-19,clinical cases,pathogen isolation,vaccines,health statistics,polymerase chain reaction (PCR) testing issues